

CST Bulletin – November, 2022

BC Cancer ST Program Updates for November 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build

What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:


- <u>For PowerPlans that are versioned</u>: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.

ZONCP BR BRAVA7 - Cycle 1	Orders		*Est. Start Date: 27-Oct-2021 08:00 PD Repeat
😰 220NCP BR BRAVA7 - Cycle 2			*Est. Start Date: 17-Nov-2021
Start Copy forward details from zz ¹ zzONCP BR BRAVA7 - Cycle 3	A new version of this plan is available. Would you like to select the new version	?	*Est. Start Date: 08-Dec-2021
22ONCP BR BRAVA7 - Cycle 4	Yes No		*Est. Start Date: 29-Dec-2021
22ONCP BR BRAVA7 - Cycle 5	Tes No		*Est. Start Date: 19-Jan-2022
22ONCP BR BRAVA7 - Cycle 6			*Est. Start Date: 09-Feb-2022
zzONCP BR BRAVA7 - Cycle 7			*Est. Start Date: 02-Mar-2022
22ONCP BR BRAVA7 - Cycle 8			*Est. Start Date: 23-Mar-2022

• **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).



Please see this month's changes below:



PowerPlan: ULYFACAL, ULYFIBRU

Cycles/PowerPlans: All associated Regimens and PowerPlans

Changes:

CAP designation of these protocols will be removed on November 1, 2022.

New Names in Cerner:

ULYFACAL → LYFACAL

$\mathsf{ULYFIBRU} \rightarrow \mathsf{LYFIBRU}$

ONC LY	ONC LY LYFIBRU (PO) (Pending)					
▼ Hide	✓ Hide additional details					
Regin	Regimen description: Treatment of Previously Untreated Chronic Lymphocytic Let					
0+/	Add 🖺 Document Response 崎 View Responses					
⇒	ONCP LY LYFIBRU Pretreatment Plan					
St	Start					
謬	ONCP LY LYFIBRU (PO)					
38	ONCP LY LYFIBRU (PO)					
3	ONCP LY LYFIBRU (PO)					
謬	ONCP LY LYFIBRU (PO)					

Versioning: Yes

Jira: CST-186937, CST-186945





A joint initiative of: Vancouver Coastal Health, the Provincial Health Services Authority, and Providence Health Care

PowerPlan: GOTDEMACO

Cycles/PowerPlans: GOTDEMACO (inpatient and outpatient)

Changes:

In the Inpatient Chemotherapy phase:

- Updated treatment schedule to be Days 1 to 7.
- Added yellow note under etoposide IV: If dose modification is required, omit etoposide IV and choose etoposide PO. If ordering etoposide PO, it must also be ordered in Prescriptions Phase.
- Added PO etoposide for Days 1 to 7.
- Mutually excluded both etoposide orders.

ONCP GO GOTDEMACO (Inpatient and Outpatient) - Cycle 1, Inpatient Chemotherapy (Day 1 to 7) (Future Pending) *Est. 20-Oct-2022 11:02 PDT - 14 Days										
			Da	y 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
	S	Component	Future	Pending	Future Pending	Future Pending	Future Pending	Future Pending	Future Pending	Future Pending
	or Component		*Est. 20-Oc		*Est. 21-Oct-2022 11:	*Est. 22-Oct-2022 11:	*Est. 23-Oct-2022 11:	*Est. 24-Oct-2022 11:	*Est. 25-Oct-2022 11:	*Est. 26-Oct-2022 11
				Actions 🔻	Actions 🔻	Actions 🔻	Actions 🔻	Actions 🔻	Actions 🔻	Actions
V	[🔗 DACTINomycin (DACTINomycin	- oncology (CAPPED))		0 min					
		0.5 mg, IV, once oncology, drug form	: syringe-inj							
		INPATIENT Days 1 and 2		ined	Planned					
	[📲 🐵 🖑 etoposide (etoposide - oncology)			+10 min					
		100 mg/m2, IV, once oncology, admir								
		Use non-DEHP tubing with 0.2 micror			Planned					
		If dose modification is required, o								
	_	choose etoposide PO. If ordering also be ordered in Prescriptions P								
	-			+10 min	+ 10 min	+10 min	+10 min	+10 min	+ 10 min	. 10
F		etoposide (etoposide - oncology)		+ 10 min	+ 10 min	+ 10 min	+ 10 min	+ 10 min	+ 10 min	+10 m
		50 mg, PO, once oncology, drug form	i: cap, Use Patient Sup							
		Days 1 to 7								1

Added a new Prescriptions Phase with:

- Yellow note at the top: If dose modification is required, omit etoposide IV and order etoposide PO. If ordering etoposide PO, it must also be ordered in Inpatient Chemotherapy Phase.
- PO etoposide.

ONCP GO GOTDEMACO (Inpatient and Outpatient) - Cycle 1, Prescriptions (Future Pending)			
	🌐 🏈 If dose modification is requ	uired, omit etoposide IV and order etoposide PO. If ordering etoposide PO, it must also be ordered in Inpatient Chemotherapy Phase	
	📕 etoposide	50 mg, PO, as directed, Take once daily on days 1-7 of each cycle, drug form: cap, dispense qty: 14 day Dispense quantity = 1 cycle	
Versioning: Yes			
Jira: CST-186363			





PowerPlan: ULYFIBRU, LYIBRU, LYMIBRU

Cycles/PowerPlans: Pretreatment and Treatment powerplans

Changes:

In the Diagnostics Phase:

• Added optional MUGA and Echocardiogram/CARD Echo.

,	component	Juius	DOSC	
ONCP LY LYFIBRU Pretreatment Plan, Diagnostics (Future Pending				
٩	If clinically indicated:			
	Electrocardiogram 12 Lead			
	NM MUGA			
	CARD Echo			

Versioning: Yes

Jira: CST-186945, CST-186947

Jira Ticket #	CST-186947, CST-186945, CST-186937, CST-186363, CST-186017
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444

